DESCRIPTION:
Gilead 934 is an ongoing study that started with 509 patients with
viral loads over 10,000. It compares once-daily Viread (tenofovir),
Emtriva (emtricitabine) and Sustiva (efavirenz) to a twice-daily
regimen of Combivir (AZT plus 3TC) and Sustiva in treatment-naive
patients.
FINDINGS:
In July 2005, 48 weeks into the full 144-week trial, data showed that
viral loads decreased in patients taking Viread, Emtriva and Sustiva
more than they did in the Combivir patients (84% versus 73%,
respectively). In addition, people in the Viread/Emtriva arm had CD4
count gains of 190 cells, compared to 158-cell gains in the Combivir
arm.
A total of 33
patients quit the study because of side effects. More patients (23)
taking Combivir quit because of anemia and other side effects such as
fatigue and nausea than in the Viread/Emtriva group (10). Also,
patients taking Combivir had lower limb fat, which may be associated
with lipoatrophy. Very few people in either arm of the study developed
resistance over the 48-week period.
MORE INFO:
http://www.rocheusa.com
